Drugs.com - New Drug Approvals

FDA Approves Odactra for the Treatment of House Dust Mite Allergy in Young Children

February 27, 2025 -- ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s Odactra tablet for use in young children with house dust mite (HDM) allergy. Odactra is now indicated to treat...

Mar 1, 2025 - 01:03
 0
FDA Approves Odactra for the Treatment of House Dust Mite Allergy in Young Children
February 27, 2025 -- ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s Odactra tablet for use in young children with house dust mite (HDM) allergy. Odactra is now indicated to treat...
Read More

Tags:

Previous Article

Ravaged by Helene, I-40 in North Carolina to reopen, with limits

Next Article

One in Six Parents Support Teens Getting Nonsurgical Cosmetic Procedures

Related Posts

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

U.S. FDA Approves Pfizer’s Adcetris Combination Regimen...

Feb 13, 2025  0

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn's Disease, Expanding Its Use to the Second Major Type of Inflammatory Bowel Disease

FDA Approves Lilly's Omvoh (mirikizumab-mrkz) for Crohn...

Feb 9, 2025  0

Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis

Galderma Receives U.S. FDA Approval for Nemluvio (nemol...

Feb 9, 2025  0